Home › Diffuse Large B-Cell Lymphoma › North Dakota
Diffuse Large B-Cell Lymphoma clinical trials in North Dakota
4 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in North Dakota.
Cities in North Dakota
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Essentia Health Cancer Center-South University Clinic, Fargo
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06649812A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Sanford Health Roger Maris Cancer Center ( Site 0189), Fargo
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06717347Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 2, 2026 · NCT05633615From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.